At a glance

ClinicalIndex Comparison Record

Phase 1Completed· 33 enrolled

Drug / intervention

RAD001drug

Likely dose

RAD001 10 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00401778

NCT00401778Phase 1Completed

Compare CT.gov

Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Emory University·interventional·Posted Nov 22, 2006·Updated Dec 21, 2016

In Brief

A Phase 1 clinical trial evaluating RAD001 for Lung Cancer. Completed, enrolled 33 participants across 1 site.

Detailed Summary

This is a Phase 1b pre-operative lung cancer trial wherein patients with operable lung cancer will be treated with RAD001 to evaluate the target effects of this compounds on relevant molecular pathways and on the 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) uptake of the tumor by a positron emission tomography (PET) scan at baseline and immediately prior to surgery. The safety profile of RAD001 will also be evaluated.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsLung Cancer

CountriesUnited States

Collaborators--

Timeline

Phase 1CompletedFinished

200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartNov 2006

First PostedNov 2006

Primary CompletionDec 2013

TodayJul 2026

First PostedNov 22, 2006

Enrollment StartNov 1, 2006

Primary CompletionDec 1, 2013

TodayJul 2, 2026

Enrollment to primary: 7.1 yearsPosted 19.6 years ago

Interventions

RAD001drug

Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.